Cohance Lifesciences Limited (NSE:COHANCE)

Cohance Lifesciences Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	596.6	1,025	472.3	648.03	445.64
Short-Term Investments	2,663	1,917	-	-	-
Trading Asset Securities	-	-	7,739	4,189	4,812
Cash & Short-Term Investments	3,260	2,942	8,211	4,837	5,258
Cash Growth	10.79%	-64.17%	69.75%	-8.00%	180.01%
Accounts Receivable	6,810	7,721	1,337	1,109	2,364
Other Receivables	19	121.1	562.3	665.92	480.04
Receivables	6,909	7,867	1,907	1,777	2,846
Inventory	5,622	4,674	2,332	3,306	3,000
Prepaid Expenses	-	-	49.2	86.28	64
Other Current Assets	2,489	2,452	32.7	103.79	111.67
Total Current Assets	18,280	17,935	12,532	10,110	11,279
Property, Plant & Equipment	21,633	20,964	7,868	7,662	5,620
Long-Term Investments	2,622	1,454	1,306	1,171	1,171
Goodwill	12,837	12,390	602.5	602.58	-
Other Intangible Assets	995.2	1,064	16.8	19.32	22.36
Long-Term Deferred Tax Assets	26.4	5.5	8.1	-	-
Other Long-Term Assets	890.6	889.6	216	91.64	203.02
Total Assets	57,296	54,810	22,549	19,657	18,296

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	2,846	2,684	423.5	700.92	1,059
Accrued Expenses	472.9	455.6	256.9	128.17	266
Short-Term Debt	-	-	385.8	445.98	471.33
Current Portion of Long-Term Debt	1,192	1,286	-	200	200
Current Portion of Leases	252.5	364.5	51.9	4.79	10.91
Current Income Taxes Payable	164.4	75.2	-	2.94	36.42
Current Unearned Revenue	-	-	6.9	8.08	-
Other Current Liabilities	1,532	2,188	49	96.79	59.27
Total Current Liabilities	6,459	7,054	1,174	1,588	2,103
Long-Term Debt	504.8	1,298	-	45.64	284.4
Long-Term Leases	2,056	1,911	212.4	7	4.63
Pension & Post-Retirement Benefits	4	2.6	-	-	11.09
Long-Term Deferred Tax Liabilities	979	1,026	656	582.35	543.15
Other Long-Term Liabilities	6,955	5,590	-	82.95	77.85
Total Liabilities	16,958	16,881	2,042	2,306	3,024

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	382.6	254.6	254.6	254.57	254.57
Additional Paid-In Capital	-	-	1,096	1,096	1,096
Retained Earnings	-	-	18,894	15,894	13,820
Comprehensive Income & Other	38,730	36,234	262.3	107.17	101.65
Total Common Equity	39,113	36,488	20,507	17,352	15,272
Minority Interest	1,225	1,441	-	-	-
Shareholders' Equity	40,338	37,929	20,507	17,352	15,272
Total Liabilities & Equity	57,296	54,810	22,549	19,657	18,296

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	4,005	4,859	650.1	703.41	971.27
Net Cash (Debt)	-745.1	-1,917	7,561	4,134	4,287
Net Cash Growth	-	-	82.90%	-3.56%	858.10%
Net Cash Per Share	-1.95	-4.99	29.70	16.24	16.84
Filing Date Shares Outstanding	383.33	382.57	254.56	254.56	254.56
Total Common Shares Outstanding	383.33	254.56	254.56	254.56	254.56
Working Capital	11,820	10,881	11,358	8,523	9,176
Book Value Per Share	102.03	143.34	80.56	68.16	59.99
Tangible Book Value	25,281	23,035	19,887	16,730	15,249
Tangible Book Value Per Share	65.95	90.49	78.12	65.72	59.90
Land	-	-	150.5	150.46	150.46
Buildings	-	-	2,206	2,200	1,813
Machinery	-	-	5,797	5,410	4,750
Construction In Progress	-	-	1,790	1,651	299.94
Leasehold Improvements	-	-	42.6	-	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 28, 2026

Data Sources Report a data error